These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37272079)

  • 1. Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with bipolar I disorder in a randomized, open-label, parallel-arm, pivotal study.
    McIntyre RS; Such P; Yildirim M; Madera-McDonough J; Zhang Z; Larsen F; Harlin M
    Curr Med Res Opin; 2023 Jul; 39(7):1021-1030. PubMed ID: 37272079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.
    Harlin M; Yildirim M; Such P; Madera-McDonough J; Jan M; Jin N; Watkin S; Larsen F
    CNS Drugs; 2023 Apr; 37(4):337-350. PubMed ID: 36961650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg: Secondary Analysis of Outcomes in Adult Patients With Schizophrenia in a Randomized, Open-label, Parallel-Arm, Pivotal Study.
    Citrome L; Such P; Yildirim M; Madera-McDonough J; Beckham C; Zhang Z; Larsen F; Harlin M
    J Clin Psychiatry; 2023 Sep; 84(5):. PubMed ID: 37672016
    [No Abstract]   [Full Text] [Related]  

  • 4. Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder.
    Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry P; Hertel P; Such P; McQuade RD; Nyilas M; Carson WH
    J Affect Disord; 2018 Feb; 227():649-656. PubMed ID: 29174738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study.
    Calabrese JR; Jin N; Johnson B; Such P; Baker RA; Madera J; Hertel P; Ottinger J; Amatniek J; Kawasaki H
    Int J Bipolar Disord; 2018 Jun; 6(1):14. PubMed ID: 29886522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of aripiprazole once-monthly versus oral aripiprazole in Chinese patients with acute schizophrenia: a multicenter, randomized, double-blind, non-inferiority study.
    Xiao L; Zhao Q; Li AN; Sun J; Wu B; Wang L; Zhang H; Zhang R; Li K; Xu X; Liu T; Zhang W; Xie S; Xu X; Tan Y; Zhang K; Zhang H; Guan N; Xian M; Uki M; Wang G
    Psychopharmacology (Berl); 2022 Jan; 239(1):243-251. PubMed ID: 34989824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2-Month Ready-to-Use Long-Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder.
    Wang Y; Harlin M; Larsen F; Wang X; Park W; Rich B; Gobburu JV; Raoufinia A
    Clin Pharmacol Drug Dev; 2024 Jun; 13(6):631-643. PubMed ID: 38602057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adults.
    Samalin L; Boudieu L; Llorca PM
    Expert Rev Neurother; 2024 Mar; 24(3):291-298. PubMed ID: 38299536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
    Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
    J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.
    Cutler AJ; Datto C; Nordenhem A; Minkwitz M; Acevedo L; Darko D
    Clin Ther; 2011 Nov; 33(11):1643-58. PubMed ID: 22054797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study.
    Vieta E; Owen R; Baudelet C; McQuade RD; Sanchez R; Marcus RN
    Curr Med Res Opin; 2010 Jun; 26(6):1485-96. PubMed ID: 20429835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms.
    Macfadden W; Adler CM; Turkoz I; Haskins JT; Turner N; Alphs L
    BMC Psychiatry; 2011 Oct; 11():171. PubMed ID: 22034906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study.
    Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry PP; Hertel P; Such P; McQuade RD; Nyilas M; Carson WH
    J Affect Disord; 2018 Dec; 241():425-432. PubMed ID: 30145513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study.
    Katagiri H; Tohen M; McDonnell DP; Fujikoshi S; Case M; Kanba S; Takahashi M; Gomez JC
    BMC Psychiatry; 2013 May; 13():138. PubMed ID: 23672672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study.
    Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry P; Hertel P; Such P; Salzman PM; McQuade RD; Nyilas M; Carson WH
    J Clin Psychiatry; 2017 Mar; 78(3):324-331. PubMed ID: 28146613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
    Meltzer HY; Risinger R; Nasrallah HA; Du Y; Zummo J; Corey L; Bose A; Stankovic S; Silverman BL; Ehrich EW
    J Clin Psychiatry; 2015 Aug; 76(8):1085-90. PubMed ID: 26114240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Efficacy of Lumateperone in Patients With Bipolar Depression With Mixed Features.
    McIntyre RS; Durgam S; Huo J; Kozauer SG; Stahl SM
    J Clin Psychiatry; 2023 Apr; 84(3):. PubMed ID: 37103915
    [No Abstract]   [Full Text] [Related]  

  • 18. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.
    Naber D; Hansen K; Forray C; Baker RA; Sapin C; Beillat M; Peters-Strickland T; Nylander AG; Hertel P; Andersen HS; Eramo A; Loze JY; Potkin SG
    Schizophr Res; 2015 Oct; 168(1-2):498-504. PubMed ID: 26232241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial.
    Niufan G; Tohen M; Qiuqing A; Fude Y; Pope E; McElroy H; Ming L; Gaohua W; Xinbao Z; Huichun L; Liang S
    J Affect Disord; 2008 Jan; 105(1-3):101-8. PubMed ID: 17531327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial.
    Findling RL; Landbloom RL; Mackle M; Wu X; Snow-Adami L; Chang K; Durgam S
    Paediatr Drugs; 2016 Oct; 18(5):367-78. PubMed ID: 27461426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.